FierceBiotech November 25, 2025

<a href="https://www.fiercebiotech.com/biotech/gilead-hatches-400m-biobucks-deal-swedish-biotechs-trex1-cancer-program" hreflang="en">Gilead hatches $400M biobucks deal for Swedish biotech’s TREX1 cancer program</a>

Swedish biotech Sprint Bioscience is selling off an early-stage TREX1 cancer program to Gilead for $14 million upfront, plus the chance to net up to $400 million in biobucks.